×

BMY – bristol-myers squibb (US:NYSE)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day BMY SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
Access the BMY Earnings page here
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny

Odd Lot

Avg. bid-ask spread

Avg. bid / ask size


Shares at ask / bid


Off exchange

Top News Decliners
2/5 Bristol-Myers says a key trial for its lung cancer drug succeeds [CNBC] -8.5%
4/16 Opdivo Plus Low-Dose Yervoy Combination Reduces the Risk of Progression or Death by 42% Versus Chemotherapy in First-Line Lung Cancer Patients with High Tumor Mutational Burden (TMB) -8.3%
10/26 Futures point to a weak open ahead of Twitter, Alphabet, Amazon earnings [CNBC] -5.5%
1/16 Bristol-Myers Squibb Co (NYSE: BMY) was downgraded by analysts at Vetr Inc. from a "hold" rating to a "sell" rating. They now have a $60.72 price target on the stock. -4.5%
7/27 Bristol-Myers Squibb Company (NYSE: BMY) was upgraded by analysts at Vetr Inc. from a "buy" rating to a "strong-buy" rating. They now have a $64.33 price target on the stock. -4.0%
4/17 Bristol-Myers Squibb (NYSE: BMY) had its "outperform" rating re-affirmed by analysts at William Blair. -3.7%
6/1 U.S. Food and Drug Administration Lifts Partial Clinical Hold on Opdivo (nivolumab)-based Combination Study in Multiple Myeloma -3.4%
4/1 FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Bristol-Myers Squibb Company to Contact the Firm -3.3%
3/22 Form DEFA14A BRISTOL MYERS SQUIBB CO -3.0%
10/16 Opdivo Alone or Combined with Yervoy Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer Patients with High Tumor Mutation Burden, in Exploratory Analysis from Phase 1/2 Study CheckMate -032 -2.7%

Don’t Miss Out On The Next BIG Stock Move